Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Non-metastatic Prostate Cancer × darolutamide × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 65 Neoplasm Metastasis 6 Prostatic Neoplasms, Castration-Resistant 5 Metastatic Castration-resistant Prostate Cancer 4 Prostatic Diseases 3 Non-metastatic Castration-resistant Prostate Cancer 3 Neoplasms 3 Breast Neoplasms 3 Urogenital Neoplasms 2 Triple Negative Breast Neoplasms 2 Salivary Gland Neoplasms 2 Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 2 Metastatic Hormone-sensitive Prostate Cancer 2 Male Urogenital Diseases 2 Genital Diseases, Male 2 Bulbo-Spinal Atrophy, X-Linked 2 Biochemically Recurrent Prostate Cancer 2 Adenocarcinoma 2 Urogenital Diseases 1 Thrombocytosis 1 Sleep Initiation and Maintenance Disorders 1 Prostate Cancer Non-Metastatic 1 Prostate Cancer Metastatic 1 Prostate Adenocarcinoma 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Neoplasms 1 Non-metastatic Prostate Cancer 1 Neoplasms by Site 1 Myeloproliferative Disorders 1

Interventions

enzalutamide 1 darolutamide 1 apalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06204302 2024-04-09

ARENA

Bayer

Non-metastatic Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡